Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma.

BACKGROUND Relating a disease state to an entire population of proteins provides an opportunity to gain new insights into a disease. METHODS Male populations of 53 patients with angiographic coronary artery disease and 53 control subjects without coronary disease from the Duke Databank for Cardiovascular Disease were established and matched for age and race as well as extremes of risk factors. Major plasma protein abnormalities were excluded. Plasma samples of each group were pooled to make large volumes (6 L each) to identify low-abundance proteins. After removal of albumin as well as immunoglobulins and enrichment of smaller proteins (<20-40 kDa), samples were separated into 12,960 fractions by cation exchange and 2 reversed-phase chromatography steps. Proteins were analyzed by liquid chromatography-electrospray ionization tandem mass spectrometry. RESULTS There were 731 plasma proteins or fragments identified. Of these proteins, 95 were differentially displayed in the case versus control populations. These represent broad categories of proteins involved with natural defenses, inflammation, growth, and coagulation. CONCLUSION We identified a large number of proteins that differ in abundance in populations with and those without angiographic coronary disease. These proteins now comprise candidates for validation studies in individual patients and in larger clinical data sets to better define disease pathways and establish novel markers for disease.

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[2]  J. W. Schaeffer,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article , 2002 .

[3]  E. Topol,et al.  Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. , 2003, Physiological genomics.

[4]  H. Ni,et al.  Association of (cid:2) A/ (cid:2) ’ Fibrinogen Levels and Coronary Artery Disease , 2022 .

[5]  P. Puddu,et al.  Association of serum IgA and C4 with severe atherosclerosis. , 1988, Atherosclerosis.

[6]  F. Harrell,et al.  Predicting survival from the coronary arteriogram: an experience-based statistical index of coronary artery disease severity , 2002 .

[7]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[8]  D. Rader,et al.  Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. , 1997, Blood.

[9]  T. Jørgensen,et al.  Heart Disease : A Population-Based Case-Control Study Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic , 2002 .

[10]  C F Starmer,et al.  A new information system for medical practice. , 1975, Archives of internal medicine.

[11]  S. Meri,et al.  Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. , 2002, The American journal of cardiology.

[12]  P. Libby,et al.  Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. , 1998, The Journal of clinical investigation.

[13]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[14]  M. Koschinsky,et al.  Defensin promotes the binding of lipoprotein(a) to vascular matrix. , 1999, Blood.

[15]  H. Ekmekçi,et al.  Plasma Vitronectin Levels in Patients with Coronary Atherosclerosis are Increased and Correlate with Extent of Disease , 2002, Journal of Thrombosis and Thrombolysis.

[16]  K. Hirata,et al.  Expression of tissue transglutaminase and elafin in human coronary artery: implication for plaque instability. , 2002, Atherosclerosis.

[17]  A. Masselot,et al.  High‐performance peptide identification by tandem mass spectrometry allows reliable automatic data processing in proteomics , 2004, Proteomics.

[18]  D. Grobbee,et al.  Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[19]  T. Veenstra,et al.  The Human Plasma Proteome , 2004, Molecular & Cellular Proteomics.

[20]  D. Hochstrasser,et al.  Industrial‐scale proteomics: From liters of plasma to chemically synthesized proteins , 2004, Proteomics.

[21]  I. Roth,et al.  Analysis of complement C3 activation products in human atherosclerotic lesions. , 1991, Atherosclerosis.

[22]  E. Topol,et al.  Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes , 2004, Journal of Medical Genetics.

[23]  A. Hamsten,et al.  Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. , 2000, Journal of the American College of Cardiology.

[24]  Weimin Zhu,et al.  Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. , 2003, Journal of proteome research.

[25]  A. Jaffe,et al.  Bedside Multimarker Testing for Risk Stratification in Chest Pain Units: The Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) Study , 2001 .

[26]  D. Rader,et al.  The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. , 2000, Blood.

[27]  A. Masselot,et al.  OLAV: Towards high‐throughput tandem mass spectrometry data identification , 2003, Proteomics.

[28]  P. Puddu,et al.  Relationship between serum C3 levels and traditional risk factors for myocardial infarction. , 1998, Acta cardiologica.

[29]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[30]  J. Michel,et al.  Proteomic analysis of human vessels: Application to atherosclerotic plaques , 2003, Proteomics.

[31]  E. Topol,et al.  Thrombospondin-4 and Its Variants: Expression and Differential Effects on Endothelial Cells , 2003, Circulation.